Imaging With a New Agent That Finds a Cancer Protein Called HER2

First-in-human Imaging With 89Zr-DFO-pertuzumab in Patients With HER2 Positive Malignancies

The purpose of this study is to test if an imaging agent called Zr-DFO-pertuzumab that finds HER2 proteins can be used to take pictures of HER2-positive cancer.

Inclusion Criteria:

• Age 21 years or greater
• Any biopsy proven HER2-positive malignancy. ASCO guidelines will be used to define HER2-positivity for breast cancer. Similar guidelines will be used for other cancer types as appropriate.
• At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol enrollment
• ECOG performance of 0-2

Exclusion Criteria:

• Life expectancy < 3 months
• Pregnancy or lactation
• Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds.